Subcutaneous DMPA (DMPA-SC) is an innovative injectable contraceptive that can dramatically expand access and choice for women. A new initiative led by PATH and John Snow Inc., the Subcutaneous DMPA Access Collaborative is working with ministries of health and partners across sectors to strengthen scale-up and build toward a robust global market for the product. For more information, visit the DMPA-SC Access Collaborative page or email FPoptions@path.org.
Publication date: January 2018
This is a test in the notes field